Becton Dickinson Gross Profit 2012-2026 | BDX
Becton Dickinson annual/quarterly gross profit history and growth rate from 2012 to 2026. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
- Becton Dickinson gross profit for the quarter ending March 31, 2026 was $2.154B, a 4.56% decline year-over-year.
- Becton Dickinson gross profit for the twelve months ending March 31, 2026 was $9.998B, a 7.67% increase year-over-year.
- Becton Dickinson annual gross profit for 2025 was $9.925B, a 8.77% increase from 2024.
- Becton Dickinson annual gross profit for 2024 was $9.125B, a 11.69% increase from 2023.
- Becton Dickinson annual gross profit for 2023 was $8.17B, a 3.62% decline from 2022.
|
Becton Dickinson Annual Gross Profit (Millions of US $) |
|
|---|---|
| 2025 | $9,925 |
| 2024 | $9,125 |
| 2023 | $8,170 |
| 2022 | $8,477 |
| 2021 | $8,631 |
| 2020 | $6,798 |
| 2019 | $8,288 |
| 2018 | $7,269 |
| 2017 | $5,965 |
| 2016 | $5,991 |
| 2015 | $4,695 |
| 2014 | $4,301 |
| 2013 | $4,171 |
| 2012 | $3,953 |
| 2011 | $3,959 |
|
Becton Dickinson Quarterly Gross Profit (Millions of US $) |
|
|---|---|
| 2026-03-31 | $2,154 |
| 2025-12-31 | $2,411 |
| 2025-09-30 | $2,799 |
| 2025-06-30 | $2,634 |
| 2025-03-31 | $2,257 |
| 2024-12-31 | $2,235 |
| 2024-09-30 | $2,487 |
| 2024-06-30 | $2,307 |
| 2024-03-31 | $2,304 |
| 2023-12-31 | $2,027 |
| 2023-09-30 | $1,702 |
| 2023-06-30 | $2,100 |
| 2023-03-31 | $2,235 |
| 2022-12-31 | $2,133 |
| 2022-09-30 | $2,077 |
| 2022-06-30 | $2,067 |
| 2022-03-31 | $2,113 |
| 2021-12-31 | $2,220 |
| 2021-09-30 | $1,695 |
| 2021-06-30 | $1,958 |
| 2021-03-31 | $2,246 |
| 2020-12-31 | $2,732 |
| 2020-09-30 | $1,427 |
| 2020-06-30 | $1,660 |
| 2020-03-31 | $1,733 |
| 2019-12-31 | $1,978 |
| 2019-09-30 | $2,267 |
| 2019-06-30 | $2,074 |
| 2019-03-31 | $1,974 |
| 2018-12-31 | $1,973 |
| 2018-09-30 | $2,094 |
| 2018-06-30 | $2,016 |
| 2018-03-31 | $1,606 |
| 2017-12-31 | $1,553 |
| 2017-09-30 | $1,578 |
| 2017-06-30 | $1,503 |
| 2017-03-31 | $1,432 |
| 2016-12-31 | $1,452 |
| 2016-09-30 | $1,553 |
| 2016-06-30 | $1,547 |
| 2016-03-31 | $1,483 |
| 2015-12-31 | $1,408 |
| 2015-09-30 | $1,430 |
| 2015-06-30 | $1,174 |
| 2015-03-31 | $1,046 |
| 2014-12-31 | $1,045 |
| 2014-09-30 | $1,102 |
| 2014-06-30 | $1,111 |
| 2014-03-31 | $1,053 |
| 2013-12-31 | $1,035 |
| 2013-09-30 | $1,087 |
| 2013-06-30 | $1,060 |
| 2013-03-31 | $1,018 |
| 2012-12-31 | $1,006 |
| 2012-09-30 | $1,001 |
| 2012-06-30 | $1,033 |
| 2012-03-31 | $988 |
| 2011-12-31 | $931 |
| 2011-09-30 | $952 |
| 2011-06-30 | $1,029 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical & Dental Supplies | $43.913B | $21.840B |
| Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional. BD Medical: BD Medical's major product lines include needles, syringes and intravenous catheters for medication delivery and generic prefilled injectables. BD Life Sciences - BD Diagnostics provides products for the safe collection and transport of diagnostics specimens to detect a broad range of infectious diseases, healthcare-associated infections and cancer. BD Biosciences produces research and clinical tools that facilitate the study of cells to gain a better understanding of normal and disease processes. With the acquisition of C.R. Bard, BD added a new segment - BD Interventional. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| McKesson (MCK) | United States | $106.025B | 23.03 |
| Cardinal Health (CAH) | United States | $50.715B | 22.43 |
| West Pharmaceutical Services (WST) | United States | $18.493B | 35.19 |
| Straumann Holding AG (SAUHY) | Switzerland | $16.902B | 0.00 |
| Cooper (COO) | United States | $13.894B | 16.52 |
| Align Technology (ALGN) | United States | $12.400B | 21.09 |
| Henry Schein (HSIC) | United States | $8.645B | 15.16 |
| Merit Medical Systems (MMSI) | United States | $4.072B | 19.84 |
| DENTSPLY SIRONA (XRAY) | United States | $2.339B | 7.36 |
| STAAR Surgical (STAA) | United States | $1.309B | 0.00 |
| CONMED (CNMD) | United States | $1.107B | 7.97 |
| Pro-Dex (PDEX) | United States | $0.165B | 19.65 |
| Lifevantage (LFVN) | United States | $0.053B | 5.46 |
| Axe Compute (AGPU) | United States | $0.022B | 0.00 |